Ascendis Pharma A/S
ASND
36 hedge funds and large institutions have $146M invested in Ascendis Pharma A/S in 2015 Q1 according to their latest regulatory filings, with 36 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$26.3M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$18.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$17.8M |
| 4 |
VM
VHCP Management
New York
|
+$14.8M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$13.3M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SCM
26
Sterling Capital Management
Charlotte,
North Carolina
| $337K | +$354K | +19,452 | New |
|
|
PI
27
Putnam Investments
Boston,
Massachusetts
| $326K | +$342K | +18,809 | New |
|
28
Bank of America
Charlotte,
North Carolina
| $293K | +$307K | +16,892 | New |
|
|
UOC
29
UBS O'Connor
Chicago,
Illinois
| $177K | +$186K | +10,228 | New |
|
|
PA
30
Perceptive Advisors
New York
| $174K | +$182K | +10,000 | New |
|
|
BIM
31
BlackRock Investment Management
Wilmington,
Delaware
| $153K | +$160K | +8,800 | New |
|
32
Morgan Stanley
New York
| $91K | +$95.5K | +5,250 | New |
|
33
Wells Fargo
San Francisco,
California
| $45K | +$46.8K | +2,575 | New |
|
|
TRCT
34
Tower Research Capital (TRC)
New York
| $23K | +$24.1K | +1,323 | New |
|
35
UBS Group
Zurich,
Switzerland
| $15K | +$15.7K | +865 | New |
|
36
Citigroup
New York
| $1K | +$1.46K | +80 | New |
|
ASND Hedge Fund Activity: Q1 2015 in Review
36 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q1 2015, worth a combined $146M.
Buyers outnumbered sellers: 36 funds opened new ASND positions and 0 closed out — a net gain of 36 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $26.3M.
- 36 institutional investors held Ascendis Pharma A/S (ASND) as of Q1 2015, up from 0 in Q4 2014.
- Funds reported $146M of Ascendis Pharma A/S stock for Q1 2015.
- 36 funds opened new Ascendis Pharma A/S positions in Q1 2015 and 0 closed out, a net change of +36 holders.
- The largest Ascendis Pharma A/S buyer in Q1 2015 was OrbiMed, an estimated $26.3M added.
Based on aggregated 13F filings for Q1 2015.